Up to now, most of the tumour vaccines reported were targeting mainly MHC class I. A number of recent studies confirmed, however, that immunizations addressing CD4+ T cells are more efficient than peptide vaccinations targeting only CD8+ cells [35], [36]. The gene discussed is CD4; the disease is neoplasm.